"Over the last 26 years, large pharmaceutical companies have missed an incredible opportunity," says Tim Coté, head of the Food & Drug Administration's Office of Orphan Product Development.
That opportunity? The development and commercialization of products to treat rare diseases (known to regulators as Orphan Drugs, defined as...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?